Dan Li, Jiongping Han, Jing Jin, Li Hong, Pan Hong, Weiying Feng
{"title":"Waldenström巨球蛋白血症患者的死亡原因:一项基于人群的研究","authors":"Dan Li, Jiongping Han, Jing Jin, Li Hong, Pan Hong, Weiying Feng","doi":"10.1016/j.clml.2025.09.005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, and death from non-WM causes has become increasingly important in treatment decisions. This study explored the causes of death in WM patients.</p><p><strong>Methods: </strong>The data from 8894 patients diagnosed with WM in the Surveillance, Epidemiology, and End Results (SEER) database from 1980 to 2016 were included. Standardized mortality ratios (SMRs) were used to assess the relative risk of death compared with that of the general US population.</p><p><strong>Results: </strong>Considering other competing events, the 5-year cumulative incidences of death from the index cancer, SMNs and noncancer causes were 8.6% (SD: 1.00e-05), 10.02% (SD: 1.17e-05) and 16.14% (SD: 1.79e-05), respectively, among WM patients. WM patients had the highest SMR for index cancer-related death, at 121.84 (95% CI, 103.8-142.11) in the first year after diagnosis, which declined thereafter. Among nonindex cancer-related deaths, hematological malignancy-related deaths were notably increased, whereas solid neoplasm deaths were elevated only 10 years after diagnosis (SMR, 1.43; 95% CI, 1.06-1.9). Among noncancer causes of death, infection, particularly among patients <50 years old, had the highest SMR (SMR, 19.01; 95% CI, 10.12-32.5). There were decreasing trends in the SMRs of index cancer-related deaths, all nonindex cancer-related deaths and many noncancer disease-related deaths from 1980 to 2001 and 2002 to 2016.</p><p><strong>Conclusions: </strong>Currently, the risk of noncancer-related deaths (mainly cardiovascular disease-related deaths) exceeds that of cancer-related deaths among WM patients. These findings may provide improved guidance regarding future health risks for WM patients.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Causes of Death Among Waldenström Macroglobulinemia Patients: A Population-Based Study.\",\"authors\":\"Dan Li, Jiongping Han, Jing Jin, Li Hong, Pan Hong, Weiying Feng\",\"doi\":\"10.1016/j.clml.2025.09.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, and death from non-WM causes has become increasingly important in treatment decisions. This study explored the causes of death in WM patients.</p><p><strong>Methods: </strong>The data from 8894 patients diagnosed with WM in the Surveillance, Epidemiology, and End Results (SEER) database from 1980 to 2016 were included. Standardized mortality ratios (SMRs) were used to assess the relative risk of death compared with that of the general US population.</p><p><strong>Results: </strong>Considering other competing events, the 5-year cumulative incidences of death from the index cancer, SMNs and noncancer causes were 8.6% (SD: 1.00e-05), 10.02% (SD: 1.17e-05) and 16.14% (SD: 1.79e-05), respectively, among WM patients. WM patients had the highest SMR for index cancer-related death, at 121.84 (95% CI, 103.8-142.11) in the first year after diagnosis, which declined thereafter. Among nonindex cancer-related deaths, hematological malignancy-related deaths were notably increased, whereas solid neoplasm deaths were elevated only 10 years after diagnosis (SMR, 1.43; 95% CI, 1.06-1.9). Among noncancer causes of death, infection, particularly among patients <50 years old, had the highest SMR (SMR, 19.01; 95% CI, 10.12-32.5). There were decreasing trends in the SMRs of index cancer-related deaths, all nonindex cancer-related deaths and many noncancer disease-related deaths from 1980 to 2001 and 2002 to 2016.</p><p><strong>Conclusions: </strong>Currently, the risk of noncancer-related deaths (mainly cardiovascular disease-related deaths) exceeds that of cancer-related deaths among WM patients. These findings may provide improved guidance regarding future health risks for WM patients.</p>\",\"PeriodicalId\":10348,\"journal\":{\"name\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clml.2025.09.005\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.09.005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Causes of Death Among Waldenström Macroglobulinemia Patients: A Population-Based Study.
Background: Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, and death from non-WM causes has become increasingly important in treatment decisions. This study explored the causes of death in WM patients.
Methods: The data from 8894 patients diagnosed with WM in the Surveillance, Epidemiology, and End Results (SEER) database from 1980 to 2016 were included. Standardized mortality ratios (SMRs) were used to assess the relative risk of death compared with that of the general US population.
Results: Considering other competing events, the 5-year cumulative incidences of death from the index cancer, SMNs and noncancer causes were 8.6% (SD: 1.00e-05), 10.02% (SD: 1.17e-05) and 16.14% (SD: 1.79e-05), respectively, among WM patients. WM patients had the highest SMR for index cancer-related death, at 121.84 (95% CI, 103.8-142.11) in the first year after diagnosis, which declined thereafter. Among nonindex cancer-related deaths, hematological malignancy-related deaths were notably increased, whereas solid neoplasm deaths were elevated only 10 years after diagnosis (SMR, 1.43; 95% CI, 1.06-1.9). Among noncancer causes of death, infection, particularly among patients <50 years old, had the highest SMR (SMR, 19.01; 95% CI, 10.12-32.5). There were decreasing trends in the SMRs of index cancer-related deaths, all nonindex cancer-related deaths and many noncancer disease-related deaths from 1980 to 2001 and 2002 to 2016.
Conclusions: Currently, the risk of noncancer-related deaths (mainly cardiovascular disease-related deaths) exceeds that of cancer-related deaths among WM patients. These findings may provide improved guidance regarding future health risks for WM patients.
期刊介绍:
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.